C
Crescent Biopharma, Inc. (CBIO)
NCM – Real Time Price. Currency in USD
18.46
-0.06 (-0.32%)
At close: May 12, 2026, 4:00 PM EDT
18.20
-0.26 (-1.41%)
After-hours: May 12, 2026, 7:08 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
18.46
-0.06 (-0.32%)
At close: May 12, 2026, 4:00 PM EDT
18.20
-0.26 (-1.41%)
After-hours: May 12, 2026, 7:08 PM EDT
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Ellie Im M.D. | Chief Medical Officer |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Dr. Jonathan McNeill M.D. | President & COO |
| Dr. Wenjie Cheng Ph.D. | Senior Vice President of Technical Operations |
| Mr. Christopher Doughty | Chief Business Officer |
| Mr. Joshua T. Brumm | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-04-29 | 10-Q | cbio-20260331.htm |
| 2026-04-21 | DEFA14A | defa14-2026proxystatementx.htm |
| 2026-03-03 | POS AM | crescentbiopharma-posam.htm |
| 2026-02-26 | S-8 | crescent-formsx8xq12026xev.htm |
| 2026-01-13 | CORRESP | filename1.htm |
| 2026-01-07 | S-1 | cbio-20260107.htm |
| 2025-12-12 | S-4 POS | cbio-20251212.htm |
| 2025-12-04 | 8-K | cbio-20251202.htm |
| 2025-11-06 | 10-Q | cbio-20250930.htm |
| 2025-07-31 | 8-K | cbio-20250729.htm |
| Mr. Richard William Scalzo M.B.A. | Chief Financial Officer |
| Mr. Ryan Lynch | Senior VP of Finance, Treasurer & Chief Accounting Officer |
| Ms. Amy Reilly | Chief Communications Officer |
| Ms. Barbara Bispham Hale J.D. | General Counsel & Corporate Secretary |